Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine randomized-withdrawal maintenance study in adults with binge eating disorder
2012-004457-88Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lisdexamfetamine in binge eating disorder (BED) (3 arms), sponsored by Takeda. Primary endpoint: Time to relapse from randomization. Started Jan 2014; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on 2012-004457-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004457-88.